COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,351 Articles (22,803 medRxiv, 8,548 bioRxiv)

Most recent first Previous |  Page 1032: Articles 10311-10320  | Next

COVID-19 severity prediction based on patient risk factors and number of vaccines received
Israel, A., Schäffer, A. A., Merzon, E., Green, I., Magen, E., Golan-Cohen, A., Vinker, S., Ruppin, E.
10.1101/2021.12.31.21268575 — Posted: 2022-01-01
Head-to-head comparison of nasal and nasopharyngeal sampling using SARS-CoV-2 rapid antigen testing in Lesotho
Labhardt, N. D., Gonzalez Fernandez, L., Katende, B., Muhairwe, J., Bresser, M., Amstutz, A., Glass, T. R., Ruhwald, M., Sacks, J. A., Escadafal, C., Mareka, M., Mookho, M. S., de Vos, M. D., Reither, K.
10.1101/2021.12.29.21268505 — Posted: 2022-01-01
Social isolation and psychological distress among southern US college students in the era of COVID-19
Giovenco, D., Shook-Sa, B. E., Hutson, B., Buchanan, L., Fisher, E. B., Pettifor, A.
10.1101/2021.12.31.21268596 — Posted: 2022-01-01
From Delta to Omicron: analysing the SARS-CoV-2 epidemic in France using variant-specific screening tests (September 1 to December 18, 2021)
Sofonea, M. T., Roquebert, B., Foulongne, V., Verdurme, L., Trombert-Paolantoni, S., Roussel, M., Haim-Boukobza, S., Alizon, S.
10.1101/2021.12.31.21268583 — Posted: 2022-01-01
Protective effect of BNT162b2 vaccination on aerobic capacity following mild to moderate SARS-CoV-2 infection: a cross sectional study, Israel, March-December 2021
Blumberg, Y., Edelstein, M., Abu Jabal, K., Golan, R., Perets, Y., Saad, M., Levinas, T., Dabbah, S., Israeli, Z., Yacoubi, S., Abu Raya, A., Amital, A., Halabi, M.
10.1101/2021.12.30.21268538 — Posted: 2022-01-01
Vaccine Effectiveness against COVID-19 among Symptomatic Persons Aged >=12 Years with Reported Contact with COVID-19 Cases, February - September 2021
Chung, J., Kim, S., Belongia, E. A., McLean, H. Q., King, J. P., Nowalk, M. P., Zimmerman, R. K., Moehling Geffel, K., Martin, E. T., Monto, A., Lamerato, L. E., Gaglani, M., Hoffman, E., Volz, M., Jackson, M. L., Jackson, L. A., Patel, M. M., Flannery, B.
10.1101/2021.12.30.21267928 — Posted: 2022-01-01
Preferential expansion of cross-reactive pre-existing switched memory B cells that recognize the SARS-CoV-2 Omicron variant Spike protein
Perugino, C. A., Liu, H., Feldman, J., Hauser, B. M., Jacob-Dolan, C., Nathan, A., Zhou, Z., Kaseke, C., Tano-Menka, R., Getz, M. A., Sanjobe, F., Berrios, C., Ofoman, O., Lemieux, J., Goldberg, M. B. A., Nundel, K., Marshak-Rothstein, A., Iafrate, J., Gaiha, G., Charles, R., Balazs, A. B., Naranbhai, V., Schmidt, A. G., Pillai, S.
10.1101/2021.12.30.21268554 — Posted: 2022-01-01
Waning of SARS-CoV-2 Antibody levels response to inactivated cellular vaccine over 6 months among healthcare workers
Taminato, M., Chaves, A. P. C., Morais, R. B. d., Moreira, L. V. L., Conte, D. D., Faico-Filho, K. S., Gabrielloni, M. C., de Medeiros, E. A., Bellei, N.
10.1101/2021.12.30.21268532 — Posted: 2022-01-01
Antibody binding and ACE2 binding inhibition is significantly reduced for the Omicron variant compared to all other variants of concern
Junker, D., Becker, M., Wagner, T., Kaiser, P. D., Maier, S., Grimm, T. M., Griesbaum, J., Marsall, P., Gruber, J., Traenkle, B., Heinzel, C., Pinilla, Y. T., Held, J., Fendel, R., Kreidenweiss, A., Nelde, A., Maringer, Y., Schroeder, S., Walz, J. S., Althaus, K., Uzun, G., Mikus, M., Bakchoul, T., Schenke-Layland, K., Bunk, S., Haeberle, H., Bitzer, M., Goepel, S., Renk, H., Remppis, J., Engel, C., Franz, A. R., Harries, M., Kessel, B., Strengert, M., Krause, G., Zeck, A., Rothbauer, U., Dulovic, A., Schneiderhan-Marra, N.
10.1101/2021.12.30.21267519 — Posted: 2022-01-01
Predicting the impact of COVID-19 vaccination campaigns - a flexible age-dependent, spatially-stratified predictive model, accounting for multiple viral variants and vaccines
Schneider, K. A., Tsoungui Obama, H. C. J., Adil Mahmoud Yousif, N., Ngougoue Ngougoue, P. M.
10.1101/2021.12.29.21268526 — Posted: 2022-01-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).